Designed in collaboration with Professor Michael Lisanti, founder of “The Autophagic Tumor Stroma Model of Cancer Metabolism”, Targeting the Tumor Microenvironment outlined exactly how knowledge of the TME can decrease attrition rates and improve the clinical success of cancer therapeutics.
Thank you to everyone who attended the October 2012 Targeting the Tumor Microenvironment meeting! There were some really fantastic presentations and a great mix of participants which made for some fascinating discussions and meetings in networking breaks.
“Very interesting meeting, very effective workshops, wonderful atmosphere” Oncotest
“Great meeting, the strongest feature being the opportunity to network with colleagues”
Thomas Jefferson University
“This meeting was a great opportunity to see the latest advancements, especially in cancer in vivo models” Nippon Kayaku
“All the presentations were relevant and very helpful. Thanks for making the conference so worthwhile” Sanofi
With presentations, discussions and industry case studies from companies such as Pfizer, Johnson & Johnson, Genentech, Threshold, Sanofi and Eli Lilly, this meeting was designed to help the industry increase the therapeutic efficacy of cancer drugs.
What was on the Agenda?
Targeting the Tumor Microenvironment was the only meeting focusing on the commercial potential of this promising science.
Look out for more detail on next year's meeting, and save the date: 21st- 23rd October 2013!